KEEP Labs Inc. | January 28, 2022
KEEP Labs, the Modern Medicine Cabinet and KARE by KEEP Adherence Platform developers, are pleased to announce a partnership with McKesson Canada to provide a novel solution for Canadians taking specialty medications.
A majority of healthcare activities occur in the home, making it a critical place to monitor, engage and support patients. KEEP's state of the art technology and intuitive design allows McKesson Canada to provide an award-winning adherence platform that supports all dosage forms, from oral to injectable therapies. This partnership extends the reach of McKesson Canada's patient engagement capabilities, allowing them to gain greater insight into how to best support patients in real-time.
KEEP and McKesson Canada are building the patient experience of the future. Despite notable advancements in new treatment options, adherence rates remain stagnant. Patient support programs have an opportunity to expand their services to drive adherence, capture real world evidence (RWE) and utilize new data sources to intelligently guide which patients can benefit most from specific interventions.
"A key function of KEEP is removing friction throughout the entire patient journey and passively capturing daily dosing events through automation in real-time, rather than relying on patients to manually input when doses are taken. When we have full visibility to the last and most important mile of the therapy journey, we have the best opportunity to intervene in a proactive and meaningful way. We're helping to enable the industry to transition from retrospective monthly data points to real-time and actionable intervention capabilities."
Jeff Wandzura, RPh, CEO of KEEP Labs
KEEP has built an integrated technology ecosystem to support providers with the data they need to make informed decisions. Patient support program providers are confronting the complexity of integrating disparate systems to deliver actionable intelligence to all stakeholders. McKesson Canada's commitment to providing an industry-leading technology stack starts by ensuring that innovative partners, like KEEP, are enhancing and complementing existing technologies through seamless integration.
The ability to intervene in real-time via nurse outreach, educational content or behavioural nudges that are configured on a program and patient archetype specific basis allows McKesson Canada to personalize the experience for each patient. These learnings are continually refined over the course of the program (using real world data), providing a first-of-its-kind data set with outcomes reported to partner organizations and members of the care team.
ABOUT KEEP LABS
KEEP Labs is a Canadian tech company founded by two dads who were looking for a smart way to store prescription medication at home. KEEP Lab's introductory product, KEEP, is a TIME Best Invention of 2020 and CES 2020 Innovation Honoree. KARE by KEEP is the first medication adherence and analytics platform for global life sciences companies, patient support programs and pharmacy networks that integrates both hardware and software for all dosage forms, providing deeper insight into the patient journey at home.
Informa Pharma Intelligence | December 06, 2021
Informa Pharma Intelligence, one of the leading business intelligence providers and knowledge partner, concluded its involvement at this year's CPhI & P-MEC Expo, a hybrid conclave hosted between 24th to 26th November 2021 at India Expo Centre – Greater Noida, New Delhi, and at the Online Conference & Networking event held between 15th to 30th November 2021.
The conclave witnessed participation from key influencers and leading figures across the pharmaceutical industry, and hosted domestic and foreign drug makers, contract service providers and pharma machinery players under one roof, providing them with a chance to craft future growth plans together.
India's pharmaceutical market is in the midst of a growth spurt, having increased in value from $21bn in 2016 to $29bn in 2020 – a figure that is expected to reach $41bn by 2024. Key industry drivers include a rise in disease prevalence, economic growth and higher disposable incomes, improvements in the healthcare infrastructure and a growth in the number of people covered by health insurance. In a bid to stay afloat during the need to step up the demand towards high quality, low-cost pharma solutions, CPhI & P-MEC India has curated a gateway to network with industry peers for the latest trends and innovative solutions that the market has to offer.
The event is geared towards building pharma community engagements, network amongst the fraternity and source innovative solutions on-site from exhibitors who have footprints both domestically and globally and cover the entire pharma supply chain - from APIs, machinery, technology, packaging, outsourcing, finished products and biopharmaceuticals. Alongside the expo, and under the aegis of the India Pharma Week, an exclusive and strategic closed door CEO Roundtable meeting took place, inviting the top leaders of India's pharmaceutical companies. The 'CEO Roundtable' was conducted on November 24 in partnership with Informa Intelligence, whose perspectives and key discussion points will also yield a white paper report.
The pharama industry is anticipated to have a steady growth trajectory and the event organised by CPhI India has focused on the key driving factors for the same. The expansion of medicine manufacturing pertaining to the evolving epidemiological profile of the country will be instrumental for India being the preferred drug manufacturing destination on a global scale. Additionally, the event aims to encourage the development of the research-based pharma fraternity.
Concluding the CPhI – P-MEC India show, Mr Poornachandra Tejasvi, Senior Director, Emerging Markets, India, at Informa Pharma Intelligence, said, "We, at Informa Pharma Intelligence, were delighted to witness the overwhelming response at CPhI & P-MEC India 2021 event and we're glad that we could partner with CPhI to host this common platform for the pharmaceutical industry. With challenges and opportunities evolving at a global scale, through this event we looked to discuss the possibilities for not only providing solutions to the healthcare needs of the country but also to the world. With India's strength in global generics market, Indian pharma and biotech companies are now gearing up to transition into R&D and innovation to establish themselves as key players to develop Biosimilars, Novel Chemical Entities, Novel Biological Entities and Innovative Therapies for the global and Indian pharmaceutical markets, for which Informa Pharma Intelligence is closely partnering to aid in this effort. The event provided a great opportunity to reconnect with our stakeholders of the pharmaceutical world and offer data intelligence and analysis on par with the recent industry trends."
"The Indian pharmaceutical market is growing exponentially, around twice the world market growth rate. While its generics market is growing strong, it is also evolving into a cradle for new drugs. Therefore, with India being one of the strongest emerging markets in the global pharma industry, it presents great opportunities for all international pharmaceutical companies to explore; we are glad that the platform by CPhI & P-MEC India could enrich the exhibitors with new pharma solutions and help businesses find the right partners, with the hybrid expo showcasing the full drug development supply-chain from exporting, outsourcing, manufacturing, machinery, regulations, pricing, and market access to, packaging, labelling, and digitalization. We look forward to hosting CPhI P-MEC in the coming year's again."
Mr.Yogesh Mudras, Managing Director, Informa Markets in India
CPhI India is a sister brand of CPhI Worldwide – A key event that all professionals from the international pharmaceutical and allied industries look forward to year on year. CPhI India and its co-located event, P-mec India, are the largest and most comprehensive pharmaceutical industry events in South Asia. This event is specifically important to the country as India is already known as the pharmacy of the world in addition to the vaccine manufacturing prowess showcased in 2019-2020.
About Informa Pharma Intelligence
Trusted by over 3,000 of the world's leading pharmaceutical, biotech, medical device companies, and CROs, the Pharma Intelligence suite of intelligence solutions, which include Datamonitor Healthcare™, Sitetrove™, Trialtrove™, Pharmaprojects™, Biomedtracker™, Scrip™, Pink Sheet™ and In Vivo™, deliver vital, accurate, and timely intelligence and analysis about the drug development pipeline to pharmaceutical and biomedical decision makers around the world. A global team of subject area experts track and analyse key diseases, clinical trials, drug approvals, and R&D activities, to deliver the data required to make critical decisions and create real-world opportunities for growth.
About CPhI Conferences
The world's largest pharmaceutical exhibition, CPhI Worldwide represents every stage of the pharmaceutical supply chain - from ingredients and FDF, to machinery, packaging, outsourcing and biopharmaceuticals.
Each year the CPhI brand unites more than 100,000 pharmaceutical professionals from all over the world through exhibitions, conferences and online communities. CPhI offers healthcare experts a chance to network, identify business opportunities and expand the global market through online and in-person interactions, with events in Europe, China, Korea, India, Japan, Southeast Asia and North America.
Eli Lilly | November 11, 2020
The U.S. just had another COVID-19 drug authorized for emergency use. But the approval is limited—and, with at least one vaccine launch on the horizon, industry watchers wonder whether drugs to treat the illness have any staying power. The FDA authorized Eli Lilly’s bamlanivimab for emergency use on Monday, making it the first antibody therapy to win that distinction. Dubbed LY-CoV555, it's an anti-SARS-CoV-2 antibody therapy the Indianapolis pharma is co-developing with AbCellera. The OK comes with some caveats: It's limited to patients 12 years and older who aren't hospitalized but who are at high risk of developing severe illness, including elderly people and those with certain underlying conditions. And Lilly is advising infusion within 10 days of symptom onset.